ArticleMycopathologia2025
Mortality and Treatment Outcomes in Pediatric Malignancy Patients with Invasive Cutaneous Fungal Infections: Evaluating the Impact of Combination Therapy and Surgical Debridement, Experience from Referral Oncology Teaching Hospital.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsInvasive cutaneous fungal infections (ICFIs) are life-threatening complications in pediatric cancer patients. This study aimed to investigate the prevalence, clinical characteristics, and outcomes of ICFIs among pediatric cancer patients hospitalized at a referral oncology teaching Hospital in Shiraz, Iran.
methodsThis cross-sectional study included pediatric patients with malignancies and suspected ICFIs who were admitted to the Amir Oncology Teaching Hospital between 2015 and 2022. Diagnosis was based on the EORTC/MSG criteria and confirmed using clinical, microbiological, and histopathological methods. Data were analyzed using descriptive statistics, Kaplan-Meier survival analysis, and comparative tests, with a significance threshold of p < 0.05.
resultsAmong the 24 patients, 58.3% were boys, and 45.8% were aged 1-5 years. Acute lymphoblastic leukemia was the most common malignancy (27.3%). Mucoralean fungi (36.4%) and Aspergillus (59.1%) were the most common. The overall survival rate was 54.2%. Proven ICFIs had the poorest outcomes, with a survival probability declining to zero by month 26. Patients with lower CRP levels and febrile neutropenia had better outcomes (p < 0.001 and p = 0.041, respectively), but survival rates did not vary significantly according to sex, age, or treatment approach (monotherapy versus combination therapy).
conclusionIn pediatric oncology patients, ICFIs are associated with high mortality, particularly in cases of mucormycosis or proven infections. Improving survival depends on early diagnosis, risk stratification, and rapid management, particularly in patients with neutropenia and fever.
Indexed as
Identifiers
41003847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.